Bausch & Lomb Corp
In the published model solve dated 2026-Q2, anchored at $17.15, Bausch & Lomb Corp (BLCO) is priced for +17.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Three segments turned at once in the March 2026 quarter: the 10-Q reports that ⟦The Pharmaceuticals segment profit was $66 million and $11 million for the three months ended March 31, 2026 and 2025⟧, with Vision Care at $202 million against $176 million and Surgical swinging to a $9 million profit from a $7 million loss. • The capital structure is the whole risk: about 5.0 billion dollars of borrowings against 268 million dollars of liquid assets, at a weighted average stated interest rate of
Is BLCO overvalued? See what's priced in →
96 institutional managers reported holding BLCO in 13F filings for the quarter ended 2026-03-31. Together they hold about 11% of the company; the top 10 hold 7%. 17 opened new positions that quarter. Held by Icahn Capital, Oaktree Capital, D. E. Shaw, among others. On the short side, 4.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (8.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BLCO's share count grew 1.5% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BLCO over the trailing three years: 2024: 1 buy totaling $505k; 2025: 2 buys totaling $268k; 2026: 9 buys totaling $1.22M. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BLCO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-04 | +0.1% | +12.1% |
| 2023-08-03 | -2.5% | -9.1% |
| 2023-11-02 | +4.7% | -2.9% |
| 2024-05-02 | -4.7% | +5.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BLCO's latest 8-K filings: 2026-08-06 (items 1.01, 5.02, 8.01, 9.01); 2026-07-29 (items 2.02, 9.01); 2026-05-20 (items 5.07); 2026-04-29 (items 2.02, 9.01); 2026-02-18 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.